뉴로진 (NGNE) 주가

뉴로진(NGNE)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $32.09 (-0.99%), 시가총액 $436.29M, 52주 범위 $14.95 ~ $34.37.

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

핵심 지표

• 현재가: $32.09 (-0.99%)
• 시가총액: $436.29M
• 52주 최저~최고: $14.95 ~ $34.37
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NAS

뉴로진의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.

뉴로진 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 매수 (4.4 / 5)

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 1.83
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문